NewAmsterdam Pharma Co N.V. cotiza a 20.19 USD y tiene una capitalización bursátil de $2.4B. En los últimos 12 meses ha facturado $7M con un margen de flujo de caja libre del -657.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.45 | $-0.34 | $-0.53 |
| Estimado | $-0.44 | $-0.43 | $-0.41 | $-0.37 |
| Sorpresa | — | -4.7% | +17.1% | -43.2% |
| Métrica | NAMS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1002.9% | -38.6% | -964.3% |
| Net Margin | -905.7% | -33.6% | -872.2% |
| FCF Margin | -657.8% | -13.9% | -644.0% |
| ROE | -29.8% | -40.4% | +10.6% |
| ROA | -26.5% | -32.0% | +5.5% |
| Current Ratio | 7.88 | 2.84 | +5.04 |
| Debt / Equity | — | 0.28 | — |